The Apple chief executive’s liver transplant went well and he has an excellent prognosis says the hospital that under-took the operation - which also emphasises there was no queue jumping. Regardless, controversy erupts. There are also questions about whether Steve Jobs has really returned to work, and securities fraud.

An oncology expert says a liver transplant could put the chief executive out of action for more than six months. He also questions the “alternative” treatment path apparently followed by the iconic Apple boss.

Professor Michael Findlay, head of the Discipline of Oncology at the University of Auckland’s School of Medical Sciences has naturally not had the opportunity to review Mr Jobs’ case first-hand.

The US Securities and Exchange Commission today opened an enquiry into Apple’s seemingly contradictory series of statements about its chief executive’s health – which have caused wild swings in the company’s share price.

It could be the upgrade of his life. Steve Jobs is actively considering a liver transplant say people involved with the Apple chief executive’s treatment, quoted anonymously by Bloomberg.

The transplant is said to be one option to address complications following Mr Jobs’ treatment for pancreatic cancer in 2004. In some cases, a pancreatic cancer tumour can spread to the liver.